Insulet listed a recommendation to handle an improper access control vulnerability in its Omnipod Insulin Management System, according to a report with CISA.
Successful exploitation of this vulnerability, discovered by Thirdwayv Inc., may allow an attacker to gain access to the affected products to intercept, modify, or interfere with the wireless RF (radio frequency) communications to or from the product. This may allow attackers to read sensitive data, change pump settings, or control insulin delivery.
An attacker with low skill level could leverage the issue, and public exploits are known for the vulnerability. This vulnerability is not exploitable remotely.
The following versions of the Omnipod Insulin Management System suffer from the issue:
- Product ID/Reorder number: 19191 and 40160
- UDI/Model/NDC number: ZXP425 (10-Pack) and ZXR425 (10-Pack Canada)
The affected insulin pump is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.
CVE-2020-10597 is the case number assigned to this vulnerability, which has a CVSS v3 base score of 7.3.
The product sees use mainly in the healthcare and public health sectors. It also sees action in the United States, Canada, and Europe.
Insulet recommends patients using the affected products talk to their healthcare provider about the risks of continued use, including the possibility of changing to the latest model with increased cybersecurity protection.
Additionally, Insulet recommends all patients take the following cybersecurity precautions:
- Do not connect to or allow any third-party devices to be connected to or use any software not authorized by Insulet
- Maintain tight physical control of the pump and devices connected to the pump
- Be attentive to pump notifications, alarms, and alerts
- Immediately cancel any unintended boluses (a single dose of insulin administered all at once)
- Monitor blood glucose levels closely and act as appropriate
- Get medical help immediately when experiencing symptoms of severe hypoglycemia or diabetic ketoacidosis or if you suspect insulin pump settings or insulin delivery has changed unexpectedly
Insulet released additional patient-focused information.
More information is available regarding Insulet’s product security and vulnerability management.